4White RH,Romano PS,Zhou H,et al.Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty.Arch Intern Med,1998,158(14):1525-1531.
5Nieuwenhuis HK,Albada J,Banga JD,et al.Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin.Blood,1991,78(9):2337-2343.
6Horn LC,Pippig S,Raptis G,et al.Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1(PAI-1)in squamous cell carcinoma of the uterine cervix.Aust N Z J Obstet Gynaecol,2002,42(4):383-386.
7Boyd DD,Kim SJ,Wang H,et al.A urokinase-derived peptide(A6)increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.Am J Pathol,2003,162(2):619-626.
8Ohta S,Fuse H,Fujiuehi Y,et al.Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.Anticancer Res,2003,23(3C):2945-2950.
9Marinho FC,Takagaki TY.Hypercoagulability and lung cancer.J Bras Pneumol,2008,34(5):312-322.
10Blais N.Diagnosing,treating,and preventing venous thromboembolism in patients with cancer.Clin J Ontol Nurs,2008,12(6):869-874.
